Design Therapeutics Reports Officer Changes
Ticker: DSGN · Form: 8-K · Filed: 2026-04-01T16:03:31-04:00
Sentiment: neutral
Topics: officer-change, director-change, compensation
TL;DR
Design Therapeutics filed an 8-K for officer changes and compensation.
AI Summary
Design Therapeutics, Inc. filed an 8-K on April 1, 2026, reporting a departure of a director or certain officer, election of directors, or appointment of certain officers, as well as compensatory arrangements for certain officers. The filing details changes in the company's leadership and executive compensation.
Why It Matters
Changes in key personnel and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Officer departures and changes in compensatory arrangements can indicate internal instability or strategic shifts that may pose risks to the company's future operations.
Key Players & Entities
- Design Therapeutics, Inc. (company) — Filer of the 8-K report
- 0001807120 (company) — CIK number for Design Therapeutics, Inc.
- 2026-04-01 (date) — Filing date of the 8-K
- 2026-03-31 (date) — Period of report for the 8-K
FAQ
What specific officer or director departed from Design Therapeutics, Inc.?
The filing indicates Item 5.02 pertains to the departure of directors or certain officers, but does not specify the name of the individual in the provided text.
Were there any new directors or officers elected or appointed?
Yes, Item 5.02 of the 8-K covers the election of directors and appointment of certain officers.
What is the filing date of this 8-K report?
The 8-K report was filed on April 1, 2026.
What is the CIK number for Design Therapeutics, Inc.?
The CIK number for Design Therapeutics, Inc. is 0001807120.
What is the primary business of Design Therapeutics, Inc. according to the filing?
Design Therapeutics, Inc. is categorized under SIC code 2834, which relates to Pharmaceutical Preparations.
From the Filing
EDGAR Filing Documents for 0001193125-26-137861 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001193125-26-137861 Filing Date 2026-04-01 Accepted 2026-04-01 16:03:31 Documents 9 Period of Report 2026-03-31 Items Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Interactive Data Document Format Files Seq Description Document Type Size 1 8-K dsgn-20260331.htm iXBRL 8-K 43554 Complete submission text file 0001193125-26-137861.txt 156142 Data Files Seq Description Document Type Size 2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT dsgn-20260331.xsd EX-101.SCH 26968 12 EXTRACTED XBRL INSTANCE DOCUMENT dsgn-20260331_htm.xml XML 5111 Mailing Address 6005 HIDDEN VALLEY ROAD SUITE 110 CARLSBAD CA 92011 Business Address 6005 HIDDEN VALLEY ROAD SUITE 110 CARLSBAD CA 92011 858-293-4900 Design Therapeutics, Inc. (Filer) CIK : 0001807120 (see all company filings) EIN. : 823929248 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-40288 | Film No.: 26828067 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)